Literature DB >> 23127558

Depletion of CSN5 inhibits Ras-mediated tumorigenesis by inducing premature senescence in p53-null cells.

Ikuko Tsujimoto1, Akihiro Yoshida, Noriko Yoneda-Kato, Jun-ya Kato.   

Abstract

The mammalian COP9 signalosome (CSN) complex is involved in cell transformation, but its molecular mechanism remains undetermined. Here we show that disruption of the fifth component (CSN5) prevented the formation of tumors by p53-null cells transformed with an active form of Ras in subcutaneously injected mice. Depletion of CSN5 suppressed cell proliferation, and induced premature senescence characterized by upregulation of senescence-associated-β-galactosidase activity and increased expression of CDK inhibitors. CSN5-depleted cells exhibited enhanced activation of the PI3 kinase-Akt pathway, and chemical inhibition of this pathway reduced the level of senescence. Thus, CSN5 is suggested to be a novel target in cancer therapy and for drugs against tumor cells harboring mutated p53.
Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23127558     DOI: 10.1016/j.febslet.2012.10.042

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

1.  An integrated bioinformatical analysis of miR-19a target genes in multiple myeloma.

Authors:  Hongyan Lv; Xianda Wu; Guiru Ma; Lixia Sun; Jianbo Meng; Xiaoning Song; Jinqiao Zhang
Journal:  Exp Ther Med       Date:  2017-09-21       Impact factor: 2.447

Review 2.  Jab1/COPS5 as a Novel Biomarker for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Human Cancer.

Authors:  Guohong Liu; Francois X Claret; Fuling Zhou; Yunbao Pan
Journal:  Front Pharmacol       Date:  2018-02-27       Impact factor: 5.810

Review 3.  Cellular senescence: the good, the bad and the unknown.

Authors:  Weijun Huang; LaTonya J Hickson; Alfonso Eirin; James L Kirkland; Lilach O Lerman
Journal:  Nat Rev Nephrol       Date:  2022-08-03       Impact factor: 42.439

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.